Chronic Heart Failure

Objectives

These national clinical recommendations provide an evidence-based framework for the diagnosis, treatment, rehabilitation, prevention and follow-up of acute and chronic heart failure in adults. Developed for use in the Russian healthcare context, they aim to improve symptoms, functional capacity, quality of life, survival and prognosis, while reducing hospitalisation, recurrent decompensation, cardiovascular mortality and sudden cardiac death.[1][2][3]

• Define heart failure as a clinical syndrome caused by structural or functional cardiac impairment, and classify it by ejection fraction, disease stage and functional limitation.[4][5][6][7]
• Identify and characterise chronic heart failure through assessment of symptoms, signs, cardiac structure and function, biomarkers, rhythm, comorbidities and underlying causes.[8][9][10][11]
• Reduce mortality and hospitalisation in symptomatic heart failure with reduced ejection fraction through disease-modifying pharmacotherapy, including renin-angiotensin system therapies, beta-blockers, mineralocorticoid-receptor antagonists and selected additional medicines.[12][13][14][15][16]
• Control congestion and improve physical functioning through individualised diuretic therapy, maintenance of euvolaemia and surveillance for electrolyte disturbance, renal dysfunction and hypotension.[17][18][19]
• Prevent sudden cardiac death and improve clinical outcomes in eligible patients through arrhythmia management, implantable cardioverter-defibrillators, cardiac resynchronisation therapy and catheter ablation where indicated.[20][21][22][23]
• Provide rapid diagnosis, stabilisation and treatment of acute heart failure to restore oxygenation and organ perfusion, relieve congestion, address precipitating causes and support safe discharge and recovery.[24][25][3]
• Promote rehabilitation, self-management and prevention through patient and family education, aerobic exercise where clinically appropriate, risk-factor modification, vaccination and early recognition of deterioration.[26][27][28][29]

Implementation

The recommendations use a patient-centred, staged clinical pathway spanning diagnostic assessment, pharmacological and device treatment, management of comorbidities, inpatient stabilisation, rehabilitation and multidisciplinary follow-up. They were prepared by Russian cardiology and heart-failure professional societies and endorsed by the Scientific and Practical Council of the Ministry of Health; their methodology adapts European Society of Cardiology guidance to national healthcare structures, service availability and clinical practice.[1][30]

• Apply structured diagnosis using history-taking, physical examination, electrocardiography, natriuretic peptides, laboratory tests, chest imaging and echocardiography, with advanced imaging or invasive investigation selected according to individual clinical need.[10][31][32][33]
• Use echocardiography to establish the heart-failure phenotype, measure ventricular structure and ejection fraction, assess valve and right-ventricular function, and repeat imaging when symptoms worsen, complications occur or treatment decisions require reassessment.[31][34][35]
• Tailor pharmacological treatment to ejection fraction, symptoms, blood pressure, rhythm, renal function, potassium concentration, congestion and treatment tolerance, with gradual initiation and dose titration towards target or maximum tolerated doses.[13][36][37][38]
• Monitor treatment safety through serial assessment of blood pressure, heart rate, body weight, symptoms, renal function, urea, creatinine, electrolytes and potassium, with defined thresholds for dose adjustment, temporary discontinuation or specialist consultation.[39][38][40][41]
• Manage atrial fibrillation and ventricular arrhythmias through assessment of reversible causes, stroke risk and anticoagulation need, ventricular-rate or rhythm control, anti-arrhythmic treatment, ablation and device therapy in selected patients.[42][43][44][45]
• Use multidisciplinary decision-making for complex interventions, including revascularisation and device implantation, involving cardiologists, cardiac surgeons and relevant diagnostic specialists; select treatment according to anatomy, ventricular function, viability, comorbidity, expected survival and patient preferences.[46][47][22]
• Deliver acute care through prompt clinical assessment, oxygenation monitoring, targeted laboratory and imaging investigations, treatment of congestion or hypoperfusion, and escalation to ventilation, vasoactive medicines or mechanical support when clinically indicated.[48][49][50][51][52]
• Coordinate discharge planning and post-discharge care through early outpatient or telephone contact, medication optimisation, repeated clinical and laboratory assessment, education for patients and relatives, and specialist multidisciplinary heart-failure follow-up.[53][54][55][56]
• Use evidence grades and recommendation classes to communicate certainty and strength, drawing on randomised trials, meta-analyses, observational evidence, registries and expert consensus.[57][58][59]

The recommendations specify clinical assessment and quality criteria, including completion of core diagnostic investigations and appropriate treatment for acute decompensation, but do not set out a national budget, financing mechanism, implementation timetable, population surveillance system or formal institutional accountability framework.[60][1]

Monitoring & Evaluation

The recommendations provide extensive patient-level clinical assessment and follow-up guidance, but no unified programme-level monitoring framework, reporting timetable, surveillance database, audit cycle, performance targets, or named accountability body. They were approved in 2020 with review planned no later than 2022, while the methodological section calls for updates at least every three years or when relevant new evidence emerges.[1][61]

• Grade recommendations using classes and evidence levels, with evidence rated from multiple randomised trials or meta-analyses to expert consensus, and recommendation strength classified as strong, conditional, or weak.[30][57][58][59]
• Assess therapeutic effectiveness through mortality, hospitalisation, symptom relief, quality of life, and functional capacity; mortality and hospitalisation are identified as the principal effectiveness criteria.[2]
• Use structured clinical measures, including New York Heart Association functional class, a clinical-condition score, and the six-minute walk test, to assess symptom burden and functional capacity.[7][62][63]
• Monitor chronic heart failure through clinical review, laboratory testing, electrocardiography and imaging as clinically indicated, including repeat echocardiography when symptoms worsen, major complications occur, device treatment is considered, or cardiotoxic treatment is planned.[11][31][64]
• Track renal function, electrolytes, blood pressure, heart rate, body weight and signs of fluid retention during disease-modifying and diuretic treatment. Specified safety monitoring includes serial potassium and creatinine testing for mineralocorticoid-receptor antagonists, and biochemical testing before and after initiation or titration of angiotensin-converting enzyme inhibitor therapy.[38][65][40][18]
• Use natriuretic peptides for diagnosis and prognosis in acute heart failure, including measurement on admission, at discharge and during outpatient care; lower concentrations at discharge are associated with lower mortality and fewer readmissions within six months.[66][67]
• Monitor acute heart failure in hospital through urine output, fluid balance, cardiac rhythm, oxygen saturation, blood pressure, daily congestion signs, renal function and electrolytes.[39]
• Undertake early post-discharge contact, either through a consultation within one week, telephone contact within three days, or a home visit within two weeks, and establish multidisciplinary follow-up after an acute episode.[56]
• Use outpatient multidisciplinary follow-up to assess treatment effectiveness, disease progression, adherence and clinical or laboratory parameters. Telephone and telemedicine monitoring are identified as follow-up mechanisms, although remote monitoring had not demonstrated prognostic benefit at the time described.[53][54][68]
• Monitor patient self-management through daily weight, pulse and symptom observation; a weight gain of more than 2 kilograms within three days should be reported to a clinician.[69][70]
• Apply a checklist-based quality assessment for heart-failure care, recording completion of core diagnostic investigations and appropriate acute and disease-modifying treatment as yes/no criteria.[60]
• Use outcomes such as repeat hospitalisation, overall mortality, cardiovascular mortality, adherence and vaccination-related outcomes to assess integrated care and prevention. Registry evidence cited reports 90-day rehospitalisation in 29.9% of patients with reduced ejection fraction and 29.2% of patients with an ejection fraction of 40%.[28][71]

Costing & Financing

No explicit costing, budget, funding source, resource-allocation mechanism, funding gap, economic assumption, or quantified financial value is provided for the clinical recommendations, diagnostic investigations, medicines, devices, rehabilitation, multidisciplinary care, telemonitoring, vaccination, or acute-care interventions.[1][64][50][60]

• Require diagnostic and monitoring resources, including laboratory testing, electrocardiography, echocardiography, chest radiography, natriuretic-peptide testing, pulse oximetry and, for selected patients, advanced imaging or invasive assessment; associated costs are not specified.[25][48][66]
• Require specialist and multidisciplinary care capacity for device therapy, revascularisation, acute treatment, outpatient follow-up, rehabilitation and patient education; no workforce, infrastructure, procurement, reimbursement, or financing arrangements are specified.[46][21][26][54]
• Identify no medicine prices, device prices, unit costs, cost-effectiveness thresholds, or budget impact estimates, including for implantable cardioverter-defibrillators, cardiac resynchronisation therapy and mechanical circulatory support.[72][73][74]
• Report that referenced literature includes work on cost-effectiveness, healthcare resource use, financial aspects and the economic burden of heart failure programmes, but the supplied material provides no usable monetary data or document-level economic analysis.[73][74][75]